Inclusion Criteria:  Patients with relapsed/refractory CD20+ diffuse large B-cell lymphoma. Age greater than 20 years and younger than 75 years old. Measurable disease Patients must have an ECOG performance status of less than or equal to 2. Patients must have recovered from toxic effects of all prior therapy before entering onto study. A treatment of drug-free interval of at least 3 weeks since the last dose of chemotherapy is required. More than 4 weeks since prior radiotherapy is required. Adequate bone marrow function Adequate renal function with calculated glomerular filtration rate > 15 mL/min Patients must have adequate liver function All patients must sign a document of informed consent indicating their awareness of the investigational nature and the risks of the study.  Exclusion Criteria:  Patients who have prior treatment with ruxolitinib or taxane for DLBCL. Pregnant or breast-feeding females. Active or uncontrolled infection. Life expectancy < 6 months Patients with brain or leptomeningeal metastases. Known hypersensitivity to ruxolitinib or paclitaxel Grade III peripheral neuropathy secondary to prior to therapy Second malignancy, except indolent cancers not on active anti-cancer therapy.